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The P2X7 receptor has recently been suggested to play a role in macrophage function. In addition, novel inhibitors of this receptor have been 
developed for treatment of rheumatoid arthritis because of their anti-inflammatory properties. Atherosclerosis is an inflammatory disease of 
the vascular wall where phagocytosis of oxLDL by macrophages is thought to be an initial step in the formation of plaques. We have previously 
discovered that a loss of function polymorphism of the P2X7 receptor gene, reduces the risk of ischemic stroke, implicating an important role for this 
receptor in atherosclerotic development. We hypothesized that the response of macrophages to oxLDL depends on P2X7 receptor activity.
In order to investigate the functional role of the P2X7 receptor in atherogenesis, we established a macrophage model derived from human 
monocytes of healthy volunteer donors. Isolated monocytes were cultured in the presence of IL-6 and M-CSF, and were subsequently exposed to 
oxLDL +/- the P2X7 inhibitor AZ11645373. Secretion of the pro-atherosclerotic cytokines IL-8 and MCP-1 were analyzed using ELISA. In addition, 
cells were stained for morphological studies and fat content.
Secreted concentrations of IL-8 and MCP-1 were found to increase in a dose-dependent manner in response to oxLDL. OxLDL-induced IL-8 and 
MCP-1 elevations were effectively prevented by pharmacological antagonism of the P2X7 receptor with the inhibitor AZ11645373 (1μM). Uptake of 
oxLDL was confirmed using oil-red-o staining of fat loaded cells. Interestingly, the intensity of oil-red-o staining was attenuated, and cell morphology 
preserved in cells treated with oxLDL and AZ11645373 compared to cells only stimulated with oxLDL.
In conclusion, our data shows that inhibition of the P2X7 receptor in human macrophages reduces oxLDL-induced secretion of the pro-
atherosclerotic cytokines IL-8 and MCP-1, attenuates oxLDL uptake, and preserves macrophage cell morphology. This has implications both 
for understanding purinergic control of macrophages as well as identifying the receptor as a potential novel drug target in the prevention of 
atherosclerosis.
